Comparative Pharmacology
Head-to-head clinical analysis: MINITRAN versus NITRO DUR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MINITRAN versus NITRO DUR.
MINITRAN vs NITRO-DUR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nitroglycerin is converted to nitric oxide (NO) in vascular smooth muscle, which activates guanylyl cyclase, increasing cGMP levels. This leads to dephosphorylation of myosin light chains and vasodilation, particularly in venous capacitance vessels and coronary arteries, reducing preload and afterload.
Nitroglycerin is a prodrug that is converted to nitric oxide (NO) in vascular smooth muscle, activating guanylyl cyclase, increasing cGMP, leading to vasodilation primarily in veins and arteries.
Minitran (nitroglycerin transdermal) is applied as a transdermal patch. Initial dose: 0.2-0.4 mg/hour applied once daily. Titrate based on response and tolerance. Maximum dose: 0.8 mg/hour. The patch is worn for 12-14 hours daily with a 10-12 hour nitrate-free interval to prevent tolerance.
Transdermal: Initial 0.2-0.4 mg/h applied once daily, titrate to 0.4-0.8 mg/h; maximum 0.8 mg/h. Remove for 10-12 hours daily to prevent tolerance.
None Documented
None Documented
Terminal half-life is approximately 1-4 minutes for nitroglycerin; clinical effect duration is longer due to tissue distribution.
2–3 minutes (nitroglycerin); prolonged to ~30 minutes for active metabolites. Clinical context: Requires frequent dosing or continuous administration for sustained effect.
Primarily renal excretion of inactive metabolites; less than 1% excreted unchanged. Biliary/fecal elimination is minimal.
Primarily renal (>80% as inactive metabolites; <1% unchanged nitroglycerin). Minor biliary/fecal elimination.
Category C
Category C
Nitrate Vasodilator
Nitrate Vasodilator